Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2018-03-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle raised funds. It details the company's purchase and redemption of bank wealth management products, including amounts, dates, and yields. The document is relatively short (2006 characters) and focuses on updates about the company's use of idle raised funds for cash management, which is a financing activity. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not an earnings release or audit report. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities related to the management of raised funds.
2018-03-01 Chinese
关于控股子公司取得医疗器械经营许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (764 characters) about a controlling subsidiary obtaining a medical device business license. It includes details about the license and its impact on the company. There is no financial data, no mention of a report being attached or published, and no indication of a full report or detailed financial statements. This is a regulatory announcement about a business license approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Interim Report, or Capital Update.
2018-02-27 Chinese
关于控股孙公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the completion of business registration and obtaining a business license for a controlling subsidiary company. It details the establishment of a new subsidiary, its board composition, registered capital, and business scope. There is no financial data, no mention of a report or filing, and the content is about corporate structural update and registration completion. This fits best under a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate structure and registration, not a financial report or management change announcement.
2018-02-09 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of bank wealth management products. It includes specific dates, amounts, and yields of financial products but does not contain comprehensive financial statements or analysis typical of financial reports. The document is relatively short (2391 characters) and serves as an update on financing activities related to idle raised funds. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2018-02-01 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and redemption of various financial products such as open-ended wealth management products, structured deposits, and fixed deposits. The document includes specific transaction dates, amounts, and yields, but it is primarily an update on financing activities related to cash management rather than a full financial report or earnings release. The document length is 2205 characters, which is relatively short and focused on a specific financing update. There is no indication that this is an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it provides detailed information on the company's financing activities involving idle funds and cash management products.
2018-02-01 Chinese
2017年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2017 annual performance forecast (业绩预告) issued by the company's board, providing preliminary estimates of revenue and net profit growth for the full fiscal year 2017. It explicitly states that the forecast is unaudited and that the final audited financial data will be disclosed in the formal 2017 annual report. The document is short (1106 characters) and serves as an earnings preview rather than a full financial report. It does not contain actual financial statements or detailed analysis, only preliminary performance expectations. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of periodic financial results highlights. FY 2017
2018-01-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.